Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

Abstract Background Quinoline-3-carboxamides, such as laquinimod, ameliorate CNS autoimmunity in patients and reduce tumor cell metastasis experimentally. Previous studies have focused on the immunomodulatory effect of laquinimod on myeloid cells. The data contained herein suggest that quinoline-3-c...

Full description

Bibliographic Details
Main Authors: Martina Ott, Erika Avendaño-Guzmán, Evelyn Ullrich, Carolin Dreyer, Judith Strauss, Markus Harden, Margarete Schön, Michael P. Schön, Günter Bernhardt, Christine Stadelmann, Christiane Wegner, Wolfgang Brück, Stefan Nessler
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Neuroinflammation
Subjects:
Quinoline-3-carboxamide
Laquinimod
Natural killer cells
Aryl hydrocarbon receptor
Dendritic cells
DNAM-1/CD155 interactions
Online Access:http://link.springer.com/article/10.1186/s12974-019-1437-0

Internet

http://link.springer.com/article/10.1186/s12974-019-1437-0

Similar Items